RNA kinetics influence the response to transcriptional perturbation in leukaemia cell lines
- Author(s)
- Todorovski, I; Tsang, MJ; Feran, B; Fan, Z; Gadipally, S; Yoannidis, D; Kong, IY; Bjelosevic, S; Rivera, S; Voulgaris, O; Zethoven, M; Hawkins, ED; Simpson, KJ; Arnau, GM; Papenfuss, AT; Johnstone, RW; Vervoort, SJ;
- Details
- Publication Year 2024-12,Volume 6,Issue #4,Page zcae039
- Journal Title
- NAR Cancer
- Publication Type
- Research article
- Abstract
- Therapeutic targeting of dysregulated transcription has emerged as a promising strategy for the treatment of cancers, such as leukaemias. The therapeutic response to small molecule inhibitors of Bromodomain-Containing Proteins (BRD), such as BRD2 and BRD4, P300/cAMP-response element binding protein (CBP) and Cyclin Dependent Kinases (CDKs), is generally attributed to the selective disruption of oncogenic gene expression driven by enhancers, super-enhancers (SEs) and lineage-specific transcription factors (TFs), including the c-MYC oncogene. The selectivity of compounds targeting the transcriptional machinery may be further shaped by post-transcriptional processes. To quantitatively assess the contribution of post-transcriptional regulation in responses to transcription inhibition, we performed multi-omics analyses to accurately measure mRNA production and decay kinetics. We demonstrate that it is not only the selective disruption of mRNA production, but rather mRNA decay rates that largely influence the selectivity associated with transcriptional inhibition. Accordingly, genes down-regulated with transcriptional inhibitors are largely characterized by extremely rapid mRNA production and turnover. In line with this notion, stabilization of the c-MYC transcript through swapping of its 3' untranslated region (UTR) rendered c-MYC insensitive to transcriptional targeting. This failed to negate the impact on c-MYC downstream targets and did not abrogate therapeutic responses. Finally, we provide evidence that modulating post-transcriptional pathways, such as through ELAVL1 targeting, can sensitize long-lived mRNAs to transcriptional inhibition and be considered as a combination therapy approach in leukaemia. Taken together, these data demonstrate that mRNA kinetics influence the therapeutic response to transcriptional perturbation and can be modulated for novel therapeutic outcomes using transcriptional agents in leukaemia.
- Publisher
- Oxford University Press
- Department(s)
- Laboratory Research
- Publisher's Version
- https://doi.org/10.1093/narcan/zcae039
- Open Access at Publisher's Site
- https://doi.org/10.1093/narcan/zcae039
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-11-12 06:11:09
Last Modified: 2024-11-12 06:12:19